Pardon the Jimi Hendrix allusion, but it seemed appropriate given yesterday’s Supreme Court decision in Bristol-Myers Squibb Co. v. Superior Court of California, No. 16-466 (June 19, 2017), in which the California Supreme Court’s finding of specific jurisdiction against a drug manufacturer was reversed as to non-California plaintiffs, who sued alleging personal injuries due to … Continue Reading
As we last noted here, the expansive interpretation in Stengel v. Medtronic Inc. of implied preemption of state law medical device claims has been under en banc review. The en banc opinion was released late last week. It is, to put it mildly, a substantial adjustment from the view of implied preemption laid out by … Continue Reading
